Circular Genomics

Circular Genomics Adds Dr. Michael Ackermann, PhD, MBA to its Scientific Advisory Board

ALBUQUERQUE, N.M., March 18, 2024 /PRNewswire/ — Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the addition of Michael F. Ackermann, PhD, MBA to its Scientific Advisory Board (SAB). Dr. Ackermann brings significant expertise in biopharmaceutical industry including antidepressant drug development to Circular Genomics. Circular Genomics is at […]

Circular Genomics Adds Dr. Michael Ackermann, PhD, MBA to its Scientific Advisory Board Read More »

Circular Genomics Strengthens Leadership Team with Key Commercial and Research Hires

ALBUQUERQUE, N.M., Feb. 26, 2024 /PRNewswire/ — Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the appointments of Dave Karlander as Chief Commercial Officer and Vishi Srinivasan, Ph.D., as Senior Director of Clinical Research. In these new roles, Karlander will oversee and manage all commercial aspects of

Circular Genomics Strengthens Leadership Team with Key Commercial and Research Hires Read More »

Circular Genomics Raises $8.3 Million for Debut of Circular RNA Assay in Precision Psychiatry

ALBUQUERQUE, N.M., Jan. 24, 2024 /PRNewswire/ — Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the closing of an $8.3 Million Series A investment round. Led by Mountain Group Partners, this round also welcomes new investor UNM Rainforest Innovations in addition to initial investors, including Cottonwood Technology

Circular Genomics Raises $8.3 Million for Debut of Circular RNA Assay in Precision Psychiatry Read More »

Circular Genomics Announces Two Significant Steps Forward in Linking CircRNA to the Detection, Therapy Selection and Monitoring of Depressive Conditions

Albuquerque, NM, July 11, 2023 (GLOBE NEWSWIRE) — Circular Genomics, the global leader in the use of circular RNA (circRNA) biomarkers for precision psychiatry, today announced the results of a new study that shows circRNAs can be used to predict with high accuracy a patient’s response to the SSRI, Sertraline, one of the most common

Circular Genomics Announces Two Significant Steps Forward in Linking CircRNA to the Detection, Therapy Selection and Monitoring of Depressive Conditions Read More »

Precision Medicine in Mental Health Company, Circular Genomics, Appoints, Dr. Paul Sargeant as Chief Executive Officer

ALBUQUERQUE, N.M., April 27, 2023 /PRNewswire/ — Circular Genomics, the leading company in developing circular RNA-based precision medicine tools, data and diagnostics for neurology and psychiatry, has appointed Paul Sargeant, PhD, to serve as Chief Executive Officer. The company is leveraging exclusive licenses and technologies in the use of circular RNA in major depressive disorder

Precision Medicine in Mental Health Company, Circular Genomics, Appoints, Dr. Paul Sargeant as Chief Executive Officer Read More »

Circular Genomics uses RNA to stop depression meds being a guessing game

Devin Coldewey@techcrunch / 12:40 PM MDT•October 18, 2022   Image Credits: Bryce Durbin / TechCrunch For many people who live with depression, medication is an important part of managing the condition. But knowing which will work for you can be a difficult months-long process. Circular Genomics claims its new form of genetic testing can identify

Circular Genomics uses RNA to stop depression meds being a guessing game Read More »

Announcing the TechCrunch Startup Battlefield 20 companies on the Disrupt Stage

Neesha A. Tambe@neeshatambe / 9:00 AM MDT•October 18, 2022   Image Credits: TechCrunch Watch Session Recordings With An Online Pass – Book Today We’re positively thrilled that Startup Battlefield is live and in person at TechCrunch Disrupt 2022. In a new era of the legendary startup competition, TechCrunch editorial hand-selected 200 startups, out of thousands

Announcing the TechCrunch Startup Battlefield 20 companies on the Disrupt Stage Read More »

Circular Genomics Closes $4.5M Series Seed Investment

December 14, 2021 December 14, 2021 – Circular Genomics, an Albuquerque, New Mexico-based circRNA company, is pleased to announce the closing of their $4.5M Series Seed investment round. The round was co-led by Cottonwood Technology Fund III and Tramway Venture Partners along with Mountain Group Partners. Other participants in the round include several individual investors.

Circular Genomics Closes $4.5M Series Seed Investment Read More »